134 related articles for article (PubMed ID: 15743979)
1. Nonlinear pharmacokinetics of propafenone in rats and humans: application of a substrate depletion assay using hepatocytes for assessment of nonlinearity.
Komura H; Iwaki M
Drug Metab Dispos; 2005 Jun; 33(6):726-32. PubMed ID: 15743979
[TBL] [Abstract][Full Text] [Related]
2. Acute dose-dependent disposition studies of nicotinic acid in rats.
Iwaki M; Ogiso T; Hayashi H; Tanino T; Benet LZ
Drug Metab Dispos; 1996 Jul; 24(7):773-9. PubMed ID: 8818575
[TBL] [Abstract][Full Text] [Related]
3. Nonlinear pharmacokinetics of a recombinant human granulocyte colony-stimulating factor derivative (nartograstim): species differences among rats, monkeys and humans.
Kuwabara T; Kato Y; Kobayashi S; Suzuki H; Sugiyama Y
J Pharmacol Exp Ther; 1994 Dec; 271(3):1535-43. PubMed ID: 7527856
[TBL] [Abstract][Full Text] [Related]
4. [Significance of the degree of oxidative hepatic metabolism in conditioning the pharmacokinetics and the pharmacodynamics of propafenone].
Boriani G; Capucci A; Strocchi E; Marchesini B; Baroni M; Frabetti L; Ambrosioni E; Magnani B
G Ital Cardiol; 1991 May; 21(5):517-26. PubMed ID: 1936756
[TBL] [Abstract][Full Text] [Related]
5. Uptake and intracellular binding of lipophilic amine drugs by isolated rat hepatocytes and implications for prediction of in vivo metabolic clearance.
Hallifax D; Houston JB
Drug Metab Dispos; 2006 Nov; 34(11):1829-36. PubMed ID: 16882765
[TBL] [Abstract][Full Text] [Related]
6. Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics.
Yang Z; Zadjura L; D'Arienzo C; Marino A; Santone K; Klunk L; Greene D; Lin PF; Colonno R; Wang T; Meanwell N; Hansel S
Biopharm Drug Dispos; 2005 Dec; 26(9):387-402. PubMed ID: 16142720
[TBL] [Abstract][Full Text] [Related]
7. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
8. In-vitro plasma protein binding of propafenone and protein profile in eight mammalian species.
Puigdemont A; Arboix M; Gaspari F; Bortolotti A; Bonati M
Res Commun Chem Pathol Pharmacol; 1989 Jun; 64(3):435-40. PubMed ID: 2781140
[TBL] [Abstract][Full Text] [Related]
9. Analysis of hepatic metabolism affecting pharmacokinetics of propranolol in humans.
Kiriyama A; Honbo A; Iga K
Int J Pharm; 2008 Feb; 349(1-2):53-60. PubMed ID: 17765415
[TBL] [Abstract][Full Text] [Related]
10. Dose-dependent pharmacokinetics of cyclosporin A in rats: events in tissues.
Tanaka C; Kawai R; Rowland M
Drug Metab Dispos; 2000 May; 28(5):582-9. PubMed ID: 10772639
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of caffeic acid phenethyl ester and its catechol-ring fluorinated derivative following intravenous administration to rats.
Wang X; Pang J; Maffucci JA; Pade DS; Newman RA; Kerwin SM; Bowman PD; Stavchansky S
Biopharm Drug Dispos; 2009 Jul; 30(5):221-8. PubMed ID: 19544289
[TBL] [Abstract][Full Text] [Related]
12. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.
Perucca E; Cloyd J; Critchley D; Fuseau E
Epilepsia; 2008 Jul; 49(7):1123-41. PubMed ID: 18503564
[TBL] [Abstract][Full Text] [Related]
13. An evaluation method for nonlinear local disposition in rat liver and kidney.
Kato T; Yamaoka K; Takakura Y
Drug Metab Dispos; 2004 Feb; 32(2):230-4. PubMed ID: 14744945
[TBL] [Abstract][Full Text] [Related]
14. Application of substrate depletion assay for early prediction of nonlinear pharmacokinetics in drug discovery: assessment of nonlinearity of metoprolol, timolol, and propranolol.
Komura H; Kawase A; Iwaki M
J Pharm Sci; 2005 Dec; 94(12):2656-66. PubMed ID: 16258981
[TBL] [Abstract][Full Text] [Related]
15. In vitro-in vivo correlation of the pharmacokinetics of vinpocetine.
Szakács T; Veres Z; Vereczkey L
Pol J Pharmacol; 2001; 53(6):623-8. PubMed ID: 11985336
[TBL] [Abstract][Full Text] [Related]
16. Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582.
Fagerholm U; Breuer O; Swedmark S; Hoogstraate J
J Pharm Pharmacol; 2005 May; 57(5):587-97. PubMed ID: 15901348
[TBL] [Abstract][Full Text] [Related]
17. The pharmacokinetic behavior of the photosensitizer meso-tetra-hydroxyphenyl-chlorin in mice and men.
Triesscheijn M; Ruevekamp M; Out R; Van Berkel TJ; Schellens J; Baas P; Stewart FA
Cancer Chemother Pharmacol; 2007 Jun; 60(1):113-22. PubMed ID: 17009028
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of recombinant human leukemia inhibitory factor in sheep.
Segrave AM; Mager DE; Charman SA; Edwards GA; Porter CJ
J Pharmacol Exp Ther; 2004 Jun; 309(3):1085-92. PubMed ID: 14872093
[TBL] [Abstract][Full Text] [Related]
19. Dose-dependent pharmacokinetics of a new Na+/H+ exchanger inhibitor KR-33028 in rats.
Kim YH; Yoo SD; Kim YS; Lee KH; Lee HS
Biopharm Drug Dispos; 2007 Nov; 28(8):423-9. PubMed ID: 17828714
[TBL] [Abstract][Full Text] [Related]
20. Dose-dependent effect of propafenone on in vivo drug metabolism in the rat.
Chong MT; Svensson CK
Res Commun Chem Pathol Pharmacol; 1987 Nov; 58(2):147-56. PubMed ID: 3423421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
